Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe bought 10,000 shares of the business's stock in a transaction dated Tuesday, January 13th. The shares were bought at an average cost of $1.72 per share, for a total transaction of $17,200.00. Following the purchase, the chief operating officer directly owned 75,308 shares in the company, valued at approximately $129,529.76. This represents a 15.31% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.Get Acrivon Therapeutics alerts:Acrivon Therapeutics Stock PerformanceShares of NASDAQ ACRV traded up $0.04 during midday trading on Thursday, hitting $1.87. 1,214,845 shares of the company traded hands, compared to its average volume of 6,233,631. Acrivon Therapeutics, Inc. has a 12-month low of $1.05 and a 12-month high of $8.00. The firm has a market cap of $59.02 million, a P/E ratio of -0.88 and a beta of 1.73. The stock has a 50-day moving average price of $2.30 and a 200 day moving average price of $1.81. Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.10. As a group, equities analysts expect that Acrivon Therapeutics, Inc. will post -2.49 earnings per share for the current year. Wall Street Analysts Forecast GrowthSeveral brokerages recently weighed in on ACRV. HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Wall Street Zen downgraded shares of Acrivon Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. Piper Sandler lifted their price target on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a research report on Friday, January 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Acrivon Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $11.67.Check Out Our Latest Stock Analysis on Acrivon TherapeuticsHedge Funds Weigh In On Acrivon TherapeuticsA number of hedge funds have recently bought and sold shares of the company. Focus Partners Wealth bought a new stake in Acrivon Therapeutics during the 3rd quarter valued at about $36,000. Algert Global LLC purchased a new stake in shares of Acrivon Therapeutics during the third quarter valued at approximately $81,000. Two Sigma Investments LP grew its holdings in shares of Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock valued at $578,000 after buying an additional 138,033 shares during the last quarter. UBS Group AG increased its position in shares of Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company's stock valued at $1,237,000 after acquiring an additional 682,763 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Acrivon Therapeutics in the 2nd quarter worth approximately $371,000. Institutional investors own 71.62% of the company's stock. Acrivon Therapeutics Company Profile (Get Free Report)Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics. The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.Featured ArticlesFive stocks we like better than Acrivon TherapeuticsElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthA U.S. “birthright” claim worth trillions - activated quietlyExecutive Order 14330: Trump’s Biggest YetThe Crash Has Already Started (Most Just Don’t See It Yet)This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Acrivon Therapeutics Right Now?Before you consider Acrivon Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.While Acrivon Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here